Shanghai Tofflon Science Tech
Tofflon Science and Technology Group Co., Ltd. engages in the research, development, production, sales, and services of pharmaceutical equipment in China and internationally. It operates through four segments: Biotechnology, Preparation Equipment, Engineering, and Food Engineering. The company offers technological research, such as cell technology, complex preparation, injection, and OSD laborato… Read more
Shanghai Tofflon Science Tech (300171) - Net Assets
Latest net assets as of September 2025: CN¥8.09 Billion CNY
Based on the latest financial reports, Shanghai Tofflon Science Tech (300171) has net assets worth CN¥8.09 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥13.30 Billion) and total liabilities (CN¥5.21 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥8.09 Billion |
| % of Total Assets | 60.81% |
| Annual Growth Rate | 28.47% |
| 5-Year Change | 117.84% |
| 10-Year Change | 172.95% |
| Growth Volatility | 121.27 |
Shanghai Tofflon Science Tech - Net Assets Trend (2007–2024)
This chart illustrates how Shanghai Tofflon Science Tech's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shanghai Tofflon Science Tech (2007–2024)
The table below shows the annual net assets of Shanghai Tofflon Science Tech from 2007 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥8.05 Billion | -0.77% |
| 2023-12-31 | CN¥8.11 Billion | +6.09% |
| 2022-12-31 | CN¥7.64 Billion | +70.69% |
| 2021-12-31 | CN¥4.48 Billion | +21.24% |
| 2020-12-31 | CN¥3.69 Billion | +13.92% |
| 2019-12-31 | CN¥3.24 Billion | +4.02% |
| 2018-12-31 | CN¥3.12 Billion | +1.01% |
| 2017-12-31 | CN¥3.09 Billion | +2.88% |
| 2016-12-31 | CN¥3.00 Billion | +1.76% |
| 2015-12-31 | CN¥2.95 Billion | +10.14% |
| 2014-12-31 | CN¥2.68 Billion | +11.15% |
| 2013-12-31 | CN¥2.41 Billion | +8.13% |
| 2012-12-31 | CN¥2.23 Billion | +7.12% |
| 2011-12-31 | CN¥2.08 Billion | +526.20% |
| 2010-12-31 | CN¥331.97 Million | +56.72% |
| 2009-12-31 | CN¥211.83 Million | +43.79% |
| 2008-12-31 | CN¥147.32 Million | +29.58% |
| 2007-12-31 | CN¥113.69 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai Tofflon Science Tech's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 4262.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥3.06 Billion | 39.14% |
| Common Stock | CN¥765.83 Million | 9.81% |
| Other Comprehensive Income | CN¥538.05 Million | 6.89% |
| Other Components | CN¥3.45 Billion | 44.16% |
| Total Equity | CN¥7.81 Billion | 100.00% |
Shanghai Tofflon Science Tech Competitors by Market Cap
The table below lists competitors of Shanghai Tofflon Science Tech ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Genco Shipping & Trading Ltd
NYSE:GNK
|
$785.23 Million |
|
Shenzhen Sunrise New Energy Co Ltd
SHE:002256
|
$785.39 Million |
|
Financial Street Holdings Co Ltd
SHE:000402
|
$785.44 Million |
|
Draegerwerk AG & Co. KGaA Pfd.
LSE:0K5E
|
$785.53 Million |
|
NCAB Group
ST:NCAB
|
$784.83 Million |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030
|
$784.18 Million |
|
ASA Gold and Precious Metals Ltd
NYSE:ASA
|
$784.17 Million |
|
BioLife Solutions Inc
NASDAQ:BLFS
|
$784.06 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai Tofflon Science Tech's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 7,879,220,430 to 7,805,408,838, a change of -73,811,592 (-0.9%).
- Net income of 194,093,228 contributed positively to equity growth.
- Dividend payments of 182,334,939 reduced retained earnings.
- Share repurchases of 63,943,727 reduced equity.
- Other comprehensive income increased equity by 538,053,304.
- Other factors decreased equity by 559,679,458.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥194.09 Million | +2.49% |
| Dividends Paid | CN¥182.33 Million | -2.34% |
| Share Repurchases | CN¥63.94 Million | -0.82% |
| Other Comprehensive Income | CN¥538.05 Million | +6.89% |
| Other Changes | CN¥-559.68 Million | -7.17% |
| Total Change | CN¥- | -0.94% |
Book Value vs Market Value Analysis
This analysis compares Shanghai Tofflon Science Tech's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.51x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 64.19x to 1.51x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CN¥0.25 | CN¥15.80 | x |
| 2008-12-31 | CN¥0.31 | CN¥15.80 | x |
| 2009-12-31 | CN¥0.44 | CN¥15.80 | x |
| 2010-12-31 | CN¥0.71 | CN¥15.80 | x |
| 2011-12-31 | CN¥3.40 | CN¥15.80 | x |
| 2012-12-31 | CN¥3.53 | CN¥15.80 | x |
| 2013-12-31 | CN¥3.80 | CN¥15.80 | x |
| 2014-12-31 | CN¥4.19 | CN¥15.80 | x |
| 2015-12-31 | CN¥4.60 | CN¥15.80 | x |
| 2016-12-31 | CN¥4.61 | CN¥15.80 | x |
| 2017-12-31 | CN¥4.86 | CN¥15.80 | x |
| 2018-12-31 | CN¥4.72 | CN¥15.80 | x |
| 2019-12-31 | CN¥5.02 | CN¥15.80 | x |
| 2020-12-31 | CN¥5.73 | CN¥15.80 | x |
| 2021-12-31 | CN¥6.79 | CN¥15.80 | x |
| 2022-12-31 | CN¥11.69 | CN¥15.80 | x |
| 2023-12-31 | CN¥10.37 | CN¥15.80 | x |
| 2024-12-31 | CN¥10.46 | CN¥15.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai Tofflon Science Tech utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.49%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.87%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 1.67x
- Recent ROE (2.49%) is below the historical average (16.07%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 40.44% | 27.49% | 0.63x | 2.35x | CN¥34.61 Million |
| 2008 | 37.25% | 24.69% | 0.60x | 2.52x | CN¥39.06 Million |
| 2009 | 36.65% | 24.63% | 0.57x | 2.60x | CN¥55.17 Million |
| 2010 | 43.38% | 29.72% | 0.58x | 2.53x | CN¥109.92 Million |
| 2011 | 10.59% | 33.51% | 0.26x | 1.23x | CN¥12.09 Million |
| 2012 | 10.65% | 28.39% | 0.26x | 1.47x | CN¥14.29 Million |
| 2013 | 11.31% | 26.09% | 0.27x | 1.60x | CN¥30.77 Million |
| 2014 | 12.88% | 26.65% | 0.30x | 1.60x | CN¥75.06 Million |
| 2015 | 13.47% | 24.86% | 0.38x | 1.41x | CN¥99.60 Million |
| 2016 | 8.02% | 17.66% | 0.32x | 1.44x | CN¥-57.79 Million |
| 2017 | 4.12% | 7.14% | 0.40x | 1.46x | CN¥-175.79 Million |
| 2018 | 2.33% | 3.68% | 0.41x | 1.55x | CN¥-232.11 Million |
| 2019 | 4.63% | 6.44% | 0.43x | 1.65x | CN¥-169.43 Million |
| 2020 | 12.86% | 17.12% | 0.41x | 1.83x | CN¥103.15 Million |
| 2021 | 19.15% | 19.74% | 0.43x | 2.25x | CN¥395.57 Million |
| 2022 | 11.37% | 15.48% | 0.41x | 1.80x | CN¥102.31 Million |
| 2023 | 7.62% | 10.64% | 0.44x | 1.64x | CN¥-187.68 Million |
| 2024 | 2.49% | 3.87% | 0.38x | 1.67x | CN¥-586.45 Million |
Industry Comparison
This section compares Shanghai Tofflon Science Tech's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,228,595,339
- Average return on equity (ROE) among peers: 12.42%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai Tofflon Science Tech (300171) | CN¥8.09 Billion | 40.44% | 0.64x | $784.88 Million |
| Beijing Centergate Technologies Holding Co Ltd (000931) | $2.03 Billion | -9.26% | 2.64x | $356.80 Million |
| Blue Sail Medical Co Ltd (002382) | $10.54 Billion | 10.97% | 0.61x | $763.05 Million |
| Andon Health Co Ltd (002432) | $758.75 Million | 1.34% | 0.32x | $2.12 Billion |
| Allmed Medical Products Co Ltd Class A (002950) | $2.75 Billion | 15.67% | 0.82x | $346.13 Million |
| Guangzhou Improve Med Instrument (300030) | $592.55 Million | 4.90% | 0.10x | $234.74 Million |
| Truking Technology Ltd (300358) | $320.32 Million | 29.77% | 1.35x | $545.42 Million |
| Jiangxi Sanxin Medtec Co Ltd (300453) | $1.41 Billion | 16.14% | 0.58x | $438.45 Million |
| Shenyang Xingqi Pharmaceutical Co Ltd (300573) | $1.55 Billion | 13.64% | 0.15x | $1.62 Billion |
| Autek China Inc (300595) | $105.24 Million | 28.59% | 0.10x | $1.21 Billion |